# Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

> **NCT04373395** · NA · UNKNOWN · sponsor: **Zhejiang University** · enrollment: 65 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **PROCEDURE:** D-CLAG

## Key facts

- **NCT ID:** NCT04373395
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-01
- **Primary completion:** 2021-12
- **Final completion:** 2023-12
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2020-09-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04373395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04373395, "Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04373395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*